Cite

HARVARD Citation

    Wiendl, H. et al. (2022). 116  Serum immunoglobulin levels and infection risk in Phase 3 ofatumumab trials in relapsing multiple sclerosis. Journal of neurology, neurosurgery and psychiatry. 93 (6), p. A137. [Online]. 
  
Back to record